



PCT/GB 2003 / 0 0 1 6 8 4



INVESTOR IN PEOPLE

BEST AVAILABLE COPY

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 19 JUN 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

12 MAY 2003

form 1/77

77

The  
**Patent  
Office**

18APR02 E711900-4 000019  
P01/7700 0200-0208817.7

1777

**Form for grant of a patent**

*(on the back of this form. You can also  
obtain a separate explanatory  
leaflet from the Patent Office to  
accompany this form)*

17 APR 2002

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

Patent reference

P030349GB

Patent application number  
(the Patent Office will fill in this part)

0208817.7

17 APR 2002

Full name, address and postcode of the or of  
each applicant (*underline all surnames*)

EUROPEAN MOLECULAR BIOLOGY LABORATORY  
POSTFACH 102209  
69012 HEIDELBERG  
GERMANY

Patents ADP number (*if you know it*)

7901325001

If the applicant is a corporate body, give the  
country/state of its incorporation

GERMANY

JS

Title of the invention

METHOD FOR PRODUCING MONOCLONAL ANTIBODIES

Name of your agent (*if you have one*)

Carpmaels & Ransford

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(*including the postcode*)

43 Bloomsbury Square  
London  
WC1A 2RA

Patents ADP number (*if you know it*)

83001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and ( <i>if you know it</i> ) the or each application number	Country	Priority application number ( <i>if you know it</i> )	Date of filing ( <i>day / month / year</i> )
---	---------	--	---

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing ( <i>day / month / year</i> )
---	-------------------------------	---

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	20
Claim(s)	3
Abstract	
Drawing(s)	2

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application

Signature

Date

*Carpmaels & Ransford*  
Carpmaels & Ransford

17th April 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Rachel Bullett

020 7242 8692

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Method for producing monoclonal antibodies

The present invention relates to methods for producing monoclonal antibodies. In particular, the invention relates to high throughput methods for producing monoclonal antibodies more rapidly than conventional methods.

- 5 The development of monoclonal antibody-producing cell lines by somatic fusions of B lymphocytes with myeloma cells was first described by Kohler and Milstein over 25 years ago (Kohler & Milstein, 1975). Since then, monoclonal antibodies have played a central role in the exponential growth of our understanding of human physiology, biochemistry and genetics. Monoclonal antibodies are versatile and sensitive tools for detecting and  
10 localising specific biological molecules. Monoclonal antibodies can be made against any cell molecule, enabling that molecule to be identified, localised and purified. In some cases, monoclonal antibodies also help identify the function of the molecules to which they bind.

- The diagnostic and therapeutic potential of monoclonal antibodies was also quickly  
15 realised after the hybridoma technique allowed their development in the mid 1970s. Monoclonal antibodies have become key components in a vast array of clinical laboratory diagnostic tests. In addition, a large number of licensed drugs contain monoclonal antibodies and vast numbers of drugs in development are monoclonal antibodies. The clinical use of monoclonal antibodies has been improved by the development of chimeric  
20 and fully humanised monoclonal antibodies which minimise side-effects in patients.

- However, despite the central role of monoclonal antibodies in these developments in medicine and molecular biology, the process for producing and screening monoclonal antibodies has changed little since it was first developed by Kohler & Milstein in the mid-1970s. The approach most often used to produce a monoclonal antibody against a specific  
25 antigen requires a series of immunisations of mice or rats with an antigen over the course of several weeks to enhance the activation and proliferation of mature B cells producing antigen-specific antibodies. Multiple mice are generally immunised and are tested periodically for the presence of relevant serum immunoglobulin titres prior to somatic fusion. Following fusion, the supernatants of hybridomas are screened using  
30 immunoassays to identify monoclonal antibodies with a high specificity for the antigen. The time frame required for developing a monoclonal antibody using this approach is generally 3 to 9 months.

The development of RIMMS (repetitive, multiple site immunisation strategy) has enabled somatic fusions to take place just 8-14 days after the initiation of immunisation (Kilpatrick *et al*, 1997). The supernatants of the hybridomas produced can then be screened using standard immunoassays, allowing a monoclonal antibody against a specific antigen to be isolated much more quickly

However, even using RIMMS, the production and screening of monoclonal antibodies against large numbers of different antigens requires a considerable time and resources. As more and more novel proteins are discovered, there is a need for faster and more efficient methods for producing and screening monoclonal antibodies against these proteins, in order to allow their further characterisation.

#### Summary of the invention

Accordingly, the invention provides a method for producing a monoclonal antibody, said method comprising the steps of:

- a) introducing at least one candidate antigen into an animal;
- 15 b) recovering antibody-producing cells from said animal and rendering these cells into single cell suspension;
- c) generating an immortalized cell line from said single cell suspension;
- d) screening the supernatant of said immortalized cell line against a protein chip on which the candidate antigen is displayed; and
- 20 e) selecting as said monoclonal antibody, an antibody that binds to said candidate antigen

The method of the invention has considerable advantages over the methods of producing monoclonal antibodies that are currently available. As already discussed, current method for producing monoclonal antibodies against more than one antigen involve laborious immunisation and isolation protocols for each individual antigen. In contrast, in the method of the invention, the animal may be injected with multiple antigens resulting in the simultaneous production of monoclonal antibodies against multiple antigens and increasing the speed and efficiency of monoclonal antibody production. The use of a protein chip in the method of the invention accelerates the process of screening to detect monoclonal antibodies that bind to the antigen or antigens with which the animal has been injected. In addition, the protein chip is more sensitive than conventional screening assays, such as enzyme linked immunosorbent assays (ELISAs), resulting in an improved detection rate

for slow secreting hybridoma cells which would be missed using conventional screening methods.

The animal in step a) of the method of the invention may be any non-human mammalian animal. Preferably, the animal is a mouse, rat, rabbit, hamster or guinea pig. Preferably, the  
5 animal is a mouse.

In step a), either a purified candidate antigen or a mixture of purified candidate antigens may be introduced into the animal. By "purified candidate antigen" is meant that the antigen is a homogenous preparation of antigen that is substantially free from any other components. By "a mixture of purified candidate antigens" is meant that more than one  
10 purified antigen is present in the composition used for immunisation, but that the preparation is free from contaminating components for which there is no intention to elicit the production of antibodies. For example, although using conventional procedures, an animal may be immunised with multiple antigens simply by immunisation with homogenised tissue, such immunisation does not represent immunisation with purified  
15 antigens as this is defined herein, since the antigens would be contaminated with cellular debris.

Any number of purified candidate antigens may be introduced into the animal. Preferably, between 1 and 50 purified candidate antigens are introduced into the animal. The antigens may be introduced simultaneously, in the sense that they are all mixed together.  
20 Alternatively, the antigens may be introduced separately one after the other. The introduction of different antigens may be separated by a time period of days. Preferably, the period separating the introduction of different antigens is less than 48 hours, preferably less than 24 hours. Preferably, the method of introduction involves injection of the antigen(s) into the animal.

25 By the term "candidate antigen" is meant any substance capable of inducing an immune response in an animal when that candidate antigen is introduced into the animal. The term therefore includes proteinaceous substances and non-proteinaceous substances. Proteinaceous substances which are antigens include proteins and derivatives thereof, such as glycoproteins, lipoproteins and nucleoproteins and peptides. Fragments of such  
30 proteinaceous substances are also included within the term "antigen". Preferably, such fragments consist of or comprise antigenic determinants. Non-proteinaceous substances which are antigens include polysaccharides, lipopolysaccharides and nucleic acids. In

particular, the term "antigen" includes nucleic acid molecules that induce an immune response against the proteins they encode. Fragments of such non-proteinaceous substances are also included with the term "antigen". The term "antigen" further includes proteinaceous or non-proteinaceous substances linked to a carrier which are able to induce  
 5 an immune response, such as lipids or haptens upon which antigenicity is conferred when they are linked to a carrier. The antigens of the invention may be naturally occurring substances or may be synthesised by methods known in the art.

Where one purified antigen is used for immunisation, the antigen is preferably a proteinaceous substance or a nucleic acid molecule. Where the purified antigen is a  
 10 proteinaceous substance, it may be introduced alone or in the form of a fusion protein. In particular, the invention provides that the antigen may be in the form of a fusion protein expressed on the surface of a recombinant virion with the animal being injected with the recombinant virion. The production of such recombinant virions using a nucleic acid sequence encoding the proteinaceous antigen, is described in Lindley et al, 2000.

15 Where more than one purified antigen is used for immunisation, any combination of purified antigens may be used. The animal may be injected with only proteinaceous antigens, only non-proteinaceous antigens, or a mixture of both. According to one embodiment of the invention, the purified antigens are all proteinaceous. The purified antigens may be fragments derived from the same protein or different proteins. The  
 20 purified antigens may be recombinant virions derived from a cDNA library, each recombinant virion expressing a protein encoded by a cDNA from the library on its surface.

According to a further embodiment, the invention provides that multiple purified antigens are introduced into the animal in the form of nucleic acid molecules encoding proteins  
 25 against which it is desired to produce monoclonal antibodies. The nucleic acid molecules may be in DNA molecules, cDNA molecules or RNA molecules. Preferably, in this aspect of the invention, a cDNA library may be introduced into the animal. It is therefore possible to inject the animal with nucleic acid molecules encoding a protein of unknown identity and as described below, cell chips may be used to isolate an antibody against the protein  
 30 which in turn allows the protein to be purified.

Where the purified antigen is a nucleic acid molecule, it preferably consists of or comprises a DNA, cDNA or RNA sequence encoding a protein against which an immune

response is to be induced. The nucleic acid molecule may be a naked nucleic acid molecule or it may be in the form of a vector.

The vector may be a viral vector, preferably a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, alphavirus vector or any other suitable vector as will be apparent to the skilled reader. Alternatively, the nucleic acid molecule may be in the form of a non-viral vector, preferably a plasmid vector. Many such vectors are known and documented in the art (see, for example, Fernandez J.M. & Hoeffler J.P. in *Gene expression systems. Using nature for the art of expression* ed. Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto, 1998). Such vectors may additionally incorporate regulatory sequences such as enhancers, promoters, ribosome binding sites and termination signals in the 5' and 3' untranslated regions of genes, that are required to ensure that the coding sequence is properly transcribed and translated.

Alternatively, the nucleic acid molecule may be in the form polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see Curiel (1992) *Hum Gene Ther* 3:147-154, or ligand linked DNA, for example see Wu (1989) *J Biol Chem* 264:16985-16987. The nucleic acid molecule may also be in the form of DNA coated latex beads. Alternatively, the nucleic acid molecule may be encapsulated in liposomes as described, for example, in WO95/13796, WO94/23697, WO91/14445 and EP-524,968. SA 91(24):11581-11585.

Antigen may be introduced into the animal by any suitable means. Preferably, the method of introduction involves injection. The animals may be immunised with the purified antigen or antigens intrasplenically, intravenously, intraperitoneally, intradermally or subcutaneously or by any other suitable means. The means of injection will depend on the antigen or antigens being injected. For example, in the case of injection with a nucleic acid molecule a hand-held gene transfer particle gun, as described in US 5,149,655 can be used to inject the nucleic acid molecule.

In the case of a proteinaceous antigen, the dose of each antigen should preferably be in the range of between 0.01 and 1000 micrograms.

Preferably, the method of the invention comprises the additional step of supplying the animal with a booster dose of some or all of the antigens which are introduced into the animal prior to the recovery of the antibody-producing cells. The animals may be given a



booster 1-365 days after the first injection. Preferably, the animals are boosted 1 to 20 times.

Preferably, the immunisation protocols used in the methodology of the present invention are short where more than one antigen is used in order to prevent one antigen becoming immunodominant. Preferably, where the animal is immunised with more than one antigen, it is injected with a booster of each antigen or combined booster of more than one antigen 3 days after the first injection and a further booster 5 days after the initial injection with spleen tissue or lymph nodes being removed between day 6 and day 15.

Immunisation of the animal may be carried out with or without pharmaceutical carriers. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Immunisation of the animal may be carried out with or without adjuvants in addition to the pharmaceutical carriers.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminium salts (alum), such as aluminium hydroxide, aluminium phosphate, aluminium sulfate, *etc*; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59<sup>TM</sup> (WO90/14837; Chapter 10 in *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi<sup>TM</sup> adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox<sup>TM</sup>); (3) saponin adjuvants, such as QS21 or Stimulon<sup>TM</sup> (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes), which

ISCOMS may be devoid of additional detergent *e.g.* WO00/07621; (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), *etc.*), interferons (*e.g.* gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), *etc.*; (6) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) *e.g.* GB-2220221, EP-A-0689454, optionally in the substantial absence of alum when used with pneumococcal saccharides *e.g.* WO00/56358; (7) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions *e.g.* EP-A-0835318, EP-A-0735898, EP-A-0761231; (8) oligonucleotides comprising CpG motifs (Roman *et al.*, *Nat. Med.*, 1997, 3, 849-854; Weiner *et al.*, *PNAS USA*, 1997, 94, 10833-10837; Davis *et al.*, *J. Immunol.*, 1998, 160, 870-876; Chu *et al.*, *J. Exp. Med.*, 1997, 186, 1623-1631; Lipford *et al.*, *Eur. J. Immunol.*, 1997, 27, 2340-2344; Moldoveanu *et al.*, *Vaccine*, 1988, 16, 1216-1224, Krieg *et al.*, *Nature*, 1995, 374, 546-549; Klinman *et al.*, *PNAS USA*, 1996, 93, 2879-2883; Ballas *et al.*, *J. Immunol.*, 1996, 157, 1840-1845; Cowdery *et al.*, *J. Immunol.*, 1996, 156, 4570-4575; Halpern *et al.*, *Cell. Immunol.*, 1996, 167, 72-78; Yamamoto *et al.*, *Jpn. J. Cancer Res.*, 1988, 79, 866-873; Stacey *et al.*, *J. Immunol.*, 1996, 157, 2116-2122; Messina *et al.*, *J. Immunol.*, 1991, 147, 1759-1764; Yi *et al.*, *J. Immunol.*, 1996, 157, 4918-4925; Yi *et al.*, *J. Immunol.*, 1996, 157, 5394-5402; Yi *et al.*, *J. Immunol.*, 1998, 160, 4755-4761; and Yi *et al.*, *J. Immunol.*, 1998, 160, 5898-5906; International patent applications WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581) *i.e.* containing at least one CG dinucleotide, with 5-methylcytosine optionally being used in place of cytosine; (9) a polyoxyethylene ether or a polyoxyethylene ester *e.g.* WO99/52549; (10) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152); (11) a saponin and an immunostimulatory oligonucleotide (*e.g.* a CpG oligonucleotide) (WO00/62800); (12) an immunostimulant and a particle of metal salt *e.g.* WO00/23105; (13) a saponin and an oil-in-water emulsion *e.g.* WO99/11241; (14) a saponin (*e.g.* QS21) + 3dMPL + IL-12 (optionally + a sterol) *e.g.* WO98/57659; (15) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Additional examples of adjuvants that may be used include Montanide ISA 50, Hunter's TiterMax, and Gerbu Adjuvants.

- Preferred antibody-producing cells for use in the invention include B cells, T cells and stem cells. These antibody-producing cells for use in the invention may be recovered by removal of any suitable cellular components of the immune system from the animal. Preferably, antibody-producing cells are recovered from the animal by removal of the spleen, lymph nodes or bone marrow or portions thereof. These may be rendered into a single cell suspension according to step b) of the method of the invention via any suitable means. Preferably, spleen tissue, lymph nodes or bone marrow removed from the animal are rendered into a single cell suspension by mechanical disruption or enzymatic digestion with proteases. Red cells may be removed from the cell suspension by hypotonic lysis.
- 10 Preferably, the immortalized cell line specified in step c) of the method of the invention is a hybridoma cell line produced by somatic fusion of the cells in the single cell suspension to myeloma cells. Cells in the single cell suspension are fused to myeloma cells with a fusogen. Examples of myeloma cells which may be used include SP2, NS1 and NS0. Preferably, the fusogen is PEG, a virus or a method of electrofusion (Zimmermann et al.
- 15 1990).

The hybridoma cells produced by the fusion of the single cell suspension with the myeloma cells should be cultured. Preferably, the hybridoma cells are initially cultured in a selective media, such as Azaserine hypoxanthine or Hypoxanthine aminopterin thymidine, and are then transferred to a non-selective media. Preferably, the hybridoma cells are

20 culture on selective media for 7 days and are then transferred to a non-selective media for 3 days. This ensures that the growth rate of the cells increases prior to the screening step. Preferably, the steps involved in hybridoma production are conducted robotically in order to speed up the process.

Alternatively, the immortalized cell line may be a cell line generated by infection of cells

25 in the single cell suspension with an immortalizing virus. Preferably, the immortalizing virus is Epstein-Bar virus (see, for example, Epstein Barr Virus Protocols, Eds. Wilson and May, Humana Press; ISBN: 0896036901).

Step d) of the method of the invention comprises screening the supernatant of the immortalized cell line, preferably a hybridoma cell line, against a protein chip comprising

30 a candidate antigen with which the animal was immunised. As used herein, the term "protein chip" is used to encompass any microarray made up of a supporting means to which a candidate antigen has been anchored.

Where just one purified antigen has been introduced into the animal, that purified antigen and no additional antigens may be anchored on the protein chip. Where more than one purified antigen has been introduced into the animal, each purified antigen may be displayed at a different position on the protein chip, preferably at a predetermined position.

- 5 Each position on the protein chip may thus display a different antigen. Alternatively, the same antigen may be anchored to each position in a row or column of a protein chip with a different antigen being displayed in each row or column. In some cases, it may be desirable, even when the animal has been immunised with more than one purified antigen, to have a different chip for each antigen. A protein chip may have a large number, such as  
10 between 1 and 1000 purified antigens anchored at predetermined positions on a chip.

Any type of protein chip known in the art may be used in the method of invention. For example, the protein chip may be a glass slide to which the purified antigen or antigens are anchored. Where only one antigen is being tested, such a slide may be prepared simply by coating glass microscope slides with aminosilane (Ansorge, Faulstich), adding an antigen-  
15 containing solution to the slide and drying. Slides coated with aminosilane may be obtained from Telechem and Pierce for coating with the purified antigen. Preferably, such a glass slide may be coated with (6-aminohexyl) aminosilane.

Other types of protein chips which may be used in the method of the invention include a 3D gel pad (Arkenov *et al*, 2000) and microwell chips. As will be apparent to the skilled  
20 reader, types of protein chips that have not yet been conceived but which are devised in the future may well prove to be suitable for use in accordance with the present invention.

The term "protein chip" also includes microarrays of cells expressing defined cDNAs (Ziauddin *et al*, 2001) referred to herein as "cell chips". In this technique, mammalian cells are cultured on a glass slide printed in defined location with different cDNAs. Cells  
25 growing on the printed locations take up and express the cDNAs. Cell chips are particularly useful when the animal has been injected with a cDNA or a cDNA library or with a recombinant virion or virions produced from a cDNA library, as described above. In such cases, the proteins encoded by the cDNA sequences may not have been isolated. By injecting the animal with cDNAs encoding the proteins or recombinant virions expressing  
30 the cDNAs, it is possible to produce monoclonal antibodies against the proteins expressed by the cDNAs. If the same cDNAs are expressed using a cell chip, these antibodies will bind and the binding may be detected as described below. Providing that a nucleic acid

sequence encoding the protein is available, the invention in this manner enables the detection and isolation of a monoclonal antibody against that protein which may be used to purify the protein itself.

For selection of antibodies, or selection of immortalised cell lines producing such antibodies, the supernatant from the immortalised cell line or cell lines is spotted onto the protein chip or protein chips at defined positions on the chip. Spotting of supernatants is preferably done robotically, for example with a Genemachines Ominigrid arrayer, using Telechem pins. The chip is then washed to remove any unbound supernatant. At this stage, any monoclonal antibody produced by the immortalized cell line and hence in the supernatant may be bound to an antigen on the chip.

By using different elution conditions, the method allows the approximate quantification of the binding affinity of the monoclonal antibody for its binding partner. Elution agents that may be used include chaotropic agents such as guanidine hydrochloride or urea at concentrations between 10  $\mu$ molar and 8 molar or ethylene glycol in an aqueous solution of 0.01% to 100% w/v. Elutions may also be carried out using aqueous or non-aqueous solutions of glycine at concentrations of between 0.01molar and a saturated solution (preferably 200mM), at a pH of between pH9 and pH1, preferably pH3.2. High pH elutions may be carried out using aqueous or non aqueous solutions of triethylamine between 1 $\mu$ molar and a saturated solution, preferably 100mM, at a pH of between pH8 and pH13, preferably pH 11.5.

Step e) of the method of the invention involves selection of a monoclonal antibody that binds to the antigen. Preferably, this step incorporates a detection step, such as by adding a marker which will bind to bound monoclonal antibody and indicate its presence. Preferably, the marker is labelled with a label such as an enzymatic or fluorescent label that enables its presence to be detected. For example, the marker may be labelled protein A or labelled protein G. Protein A or protein G may be labelled with a fluorescent label such as Cy3 or Cy5. Alternatively, protein A or protein G may be labelled with an enzymatic label such as biotin, the presence of which can be detected by the binding of labelled strepavidin or avidin.

Preferably, the marker is an antibody that will bind to the first antibody. Preferably this antibody is labelled with a label such as an enzymatic or fluorescent labels. Preferably this

antibody is labeled with fluorescent labels as this enables equipment developed for scanning of DNA chips to be used for detection.

Preferably, the step of detecting a monoclonal antibody bound to the antigen further comprises isotyping the monoclonal antibodies. Preferably, this step of detecting and  
 5 isotyping the monoclonal antibodies comprises adding isotype-specific anti-immunoglobulin antibodies to said protein chip, wherein each anti-immunoglobulin antibody having a different isotype specificity has a different label, and detecting the presence of said labels. This method enables the simultaneous detection of the monoclonal antibody and determination of its isotype.

10 It will be appreciated that the method may employ as many different isotype-specific anti-immunoglobulin antibodies, each with a different label, as there are antibody isotypes in the animal which has been immunised. For example, if a mammal, such as a mouse, has been injected with an antigen, the step of detecting and isotyping monoclonal antibodies bound to the antigen may comprise adding an anti-IgA antibody labelled with a first label,  
 15 and/or an anti-IgD antibody labelled with a second label, and/or an anti-IgE antibody labelled with a third label, and/or an anti-IgG1 antibody labelled with a fourth label, and/or an anti-IgG2a antibody labelled with a fifth label, and/or an anti-IgG2b antibody labelled with a sixth label, and/or an anti-IgG3 antibody labelled with a seventh label, and/or an anti-IgG4 antibody labelled with a eighth label. Alternatively, the step of detecting and  
 20 isotyping monoclonal antibodies bound to the antigen may comprise adding isotype-specific anti-immunoglobulin antibodies that bind to a subset of the possible isotypes. Preferably, the isotype-specific anti-immunoglobulin antibodies comprise an anti-IgM antibody labelled with a first label and an anti-IgG antibody labeled with a second label. Preferably, the labels are fluorescent labels.

25 Detection of the label indicates the presence of a monoclonal antibody bound to an antigen and is preferably done robotically. Where the label is a fluorescent label, detection of the label and hence the presence of the monoclonal antibody may be done using equipment available for scanning protein chips. For example, scanning of the chips may be done with a GenePix 4000B scanner (Axon Instruments, Inc.) or with a Tecan LS200 or LS400  
 30 scanner. Scanning may be carried out with between 1 and 4 lasers and combinations of filters to enable visualisation of multiple fluorescent labels. Preferably, visualisation of

multiple fluorescent labels is carried out simultaneously although it may be carried out sequentially.

Images may be obtained and analysed using appropriate software such as the GenePix Pro 3.0 software (Axon Instruments, Inc.), Chipskipper software (Schwager, Ansorge) or  
5 Tecan LS200 or LS400 software.

In order to ensure that the detection of a monoclonal antibody is reliable, the screening method preferably employs various controls. For example, in the case of a protein chip coated with one antigen, not only will the supernatants from the immortalized cell lines produced by the method of the invention be spotted onto the protein chip but so will  
10 positive and negative controls. Positive controls may be in the form of previously tested monoclonal antibodies or commercially available polyclonals. Negative controls may be in the form of mock supernatants at defined positions. Another level of control is determined by the fact that each supernatant is screened against several antigens. Signals obtained against only one antigen are considered to be potential positive monoclonal antibody  
15 containing supernatants.

Positive signals on the protein chip can be traced back to a particular immortalised cell line enabling the monoclonal antibody to be isolated according to step e) of the method of the invention. Further characterisation of the antibodies identified can then be carried out.

Methods for carrying out further characterisation of the antibody may include, for example,  
20 the further step of determining the specificity of the monoclonal antibodies identified. For example, a monoclonal antibody identified by the method of the invention may be used to scan a second protein chip having a large number of different proteins anchored to its surface to establish if the monoclonal antibody binds specifically to one antigen. The scanning methods described above in the initial identification of the protein may be used to  
25 scan for its specificity. The binding specificity and affinity of the monoclonal antibodies produced by the method of the invention may be further characterised by altering the concentrations of antigen on protein chips or altering the stringency of eluting conditions, as described above.

According to a further embodiment of the first aspect of the invention, there is provided a  
30 method for producing an immortalised cell line that produces a monoclonal antibody of interest, said method comprising the steps of:

a) introducing at least one candidate antigen into an animal;

- b) recovering antibody-producing cells from said animal and rendering these cells into a single cell suspension;
- c) generating an immortalized cell line from said single cell suspension;
- d) screening the supernatant of said immortalized cell line against a protein chip on which
- 5 the candidate antigen is displayed; and
- e) selecting as said immortalised cell line, that which produces a supernatant containing an antibody that binds to said candidate antigen.

Immortalised cell lines produced by such a method are of immense utility in the generation of antibodies with tailored specificities.

- 10 According to a second aspect of the invention, there is provided a monoclonal antibody produced by a method of the invention. The invention may also be used to generate a bank of antibodies, for example, with specificities encompassing an entire organismic proteome. Such a bank of antibodies represents a further aspect of the invention.

- 15 According to a third aspect of the invention, there is provided an immortalized cell line, preferably a hybridoma cell line, which produces a monoclonal antibody according to the second aspect of the invention. This aspect of the invention also includes a bank of immortalized cell lines, preferably a bank of hybridoma cell lines. The invention may also be used to generate a bank of hybridoma cell lines, for example, that produce antibodies encompassing an entire organismic proteome.

- 20 According to a fourth aspect of the invention, there is provided a method for producing a plurality of monoclonal antibodies, each of which binds to a different purified candidate antigen, comprising introducing a plurality of purified candidate antigens into an animal. Preferably, each candidate antigen is derived from a different source. By this is meant that each antigen is derived from a different protein, a different nucleic acid and so on. It is
- 25 intended that methods of antibody production that involve injecting an animal with different fragments of the same protein are excluded from the scope of this aspect of the invention. For example, the purified candidate antigens may all be proteinaceous substances provided that they are not all fragments of the same protein.

- This method has an advantage over methods disclosed in the prior art in that it enables the
- 30 simultaneous production of more than one monoclonal antibody, each of which binds to a different purified candidate antigen.



The animal may be injected with the purified candidate antigens using any of the techniques described herein. For example, the method of this aspect of the invention may further comprise the steps of recovering antibody-producing cells such as B cells, T cells and stem cells from an immunised animal, such as by removing spleen tissue, lymph nodes  
5 or bone marrow, and rendering them into a single cell suspension. The method may further comprise generating immortalized cell lines, preferably hybridoma cell lines, from the cells the single cell suspension. Preferably, the method of this aspect of the invention comprises these steps and additionally comprises the steps of screening the supernatants of the immortalized cell lines, preferably hybridoma cell lines, against a protein chip or protein  
10 chips on which the candidate antigens are displayed; and selecting monoclonal antibodies that bind to the antigens and preferably isolating these and/or the immortalized cell lines that produce the monoclonal antibodies. Suitable procedures for generating the immortalized cell lines and subsequent screening of the supernatants are the same as those described in above in connection with the method of the first aspect of the invention. In  
15 particular, the step of detecting the monoclonal antibodies may involve simultaneous detection of the monoclonal antibodies and determination of this isotype, as described above. In addition, the method may comprise further characterisation of the monoclonal antibodies, as described above.

The invention also provides a monoclonal antibody produced by a method of this aspect of  
20 the invention. Again, this aspect of the invention may be used to generate a bank of antibodies, for example, encompassing antibodies with specificity for protein in an entire organismic proteome. Such a bank of antibodies represents a further aspect of the invention.

The invention also provides an immortalized cell line, preferably a hybridoma cell line,  
25 which produces a monoclonal antibody as described above. The invention may also be used to generate a bank of immortalized cell lines, preferably a bank of hybridoma cell lines, for example, that produce antibodies encompassing an entire organismic proteome.

According to a fifth aspect of the invention, anti-idiotypic antibodies may be generated that bind to a monoclonal antibody according to the second aspect of the invention. Anti-  
30 idiotypic antibodies are useful as they have a variable region that mimics the shape of the molecule to which the original antibody was raised. Anti-idiotypic antibodies may therefore be useful in therapy as replacements for the molecules against which the original antibody

was raised. An anti-idiotypic antibody may be produced by employing the method of the first aspect of the invention or the fourth aspect of the invention using a monoclonal antibody according to the second aspect of the invention as the purified candidate antigen.

Accordingly, this aspect of the invention provides a method of producing an anti-idiotypic antibody that binds to a monoclonal antibody according to the second aspect of the invention, the method comprising using a monoclonal antibody according to the second aspect of the invention as a purified candidate antigen in a method of the first aspect of the invention or the fourth aspect of the invention. The invention also includes anti-idiotypic antibodies generated by such methods.

- 10 According to a sixth aspect of the invention, anti-anti-idiotypic antibodies may be generated that bind to an anti-idiotypic antibody produced according to the fifth aspect of the invention. Such anti-anti-idiotypic antibodies may be produced by employing the method of the first aspect of the invention or the fourth aspect of the invention using an anti-idiotypic antibody as described above as the purified candidate antigen. This aspect of the invention
- 15 thus provides a method of producing an anti-anti-idiotypic antibody that binds to an anti-idiotypic antibody generated according to the fifth aspect of the invention, the method comprising using an anti-idiotypic antibody as described above as a purified candidate antigen in a method of the first aspect of the invention or the fourth aspect of the invention.

Various aspects and embodiments of the present invention will now be described in more detail by way of example. It will be appreciated that modification of detail may be made without departing from the scope of the invention.

#### **Brief description of the Figures:**

Figure 1: Whole image of scanned chip, where green and red spots represent positive IgG and IgM producing supernatants respectively. Close ups are to show details of specific areas of chip where good spots are to be found.

Figure 2: Comparison between chip analysis and ELISA screen. First image is negative sample (Ia < 0.5), while others are positive. Average Ic: Average total intensity of spot on 3 chips. Ia: Average contribution of spot to sum of intensities over three chips (%).

## Examples

### Immunization

An 8-week old female Balb/c mouse was injected intra-splenically with 10 µg of each of 5 10 protein antigens in 100µl phosphate buffered saline (PBS). On the third day following (day 3) the mouse was injected intra-peritoneally with 1µg of each of the same 10 protein antigens in 100µl PBS. On day 5, the same mouse was injected intravenously with 0.1µg of each of the same 10 protein antigens. On Day 8 the mouse was killed by cervical dislocation and the spleen removed and collected into Dulbecco's Modified Eagle's 10 Medium (DMEM: Life Technologies Inc.).

### Fusion

All steps are performed under sterile or aseptic conditions in a laminar flow hood. The spleen was rendered into a single-cell suspension by mechanical disruption between two frosted-end glass microscope slides. The suspension was filtered into a 50ml bar-coded 15 conical-bottomed tube (BD Falcon) through a 70µm nylon cell strainer (BD Falcon) and transferred to the robotic system.

Separately, SP2 myeloma fusion partners (ATCC) were cultured for five days prior to fusion in HM20 (DMEM, 20% Defined foetal bovine serum (Hyclone Defined), 10mM L-Glutamine, 50µM Gentamicin) and on the day of the fusion were transferred to 20 HM20/HCF/2xOPI (HM20 containing 10% Hybridoma Cloning Factor (Origen) and 2%OPI cloning supplement (Sigma)) for at least one hour at 37°C in a 5% CO<sub>2</sub> incubator.

The bar codes were read by a bar code reader and the 50ml Falcon tube loaded into the rotor by the RoMa arm on the genesis Freedom system (Tecan). The rotor was loaded into the centrifuge through the workdeck.

25 The tube was centrifuged at 100g for 10 mins at room temperature (RT) and the rotor extracted from the centrifuge. The tube was extracted from the rotor and the bar code was again read to distinguish from the balance tube. Cells were resuspended in 5ml Red Cell Lysis Buffer (Sigma) for 9 minutes at RT. HM20 was added to 50ml and the tube once again centrifuged for 10 min at RT with no brake. The supernatant solution was aspirated 30 to waste and the cells resuspended in DMEM preheated to 37°C. Cells were washed twice more by steps of centrifugation and resuspension. 50µl of cell suspension was "handed

off' to a 1.5ml microcentrifuge tube. Cells were counted using a haemocytometer counting chamber.

Simultaneously the SP2 cells were washed three times in a similar fashion and a similar aliquot (50µl) "handed off" to a 1.5 ml tube for haemocytometric counting. SP2 myelomas  
5 and spleen cells were mixed at a ratio of 1:5 (SP2:Spleen) and again centrifuged at 100g for 10 min with no brake.

The supernatant solution was entirely aspirated to waste and Polyethyleneglycol 1500 in 50% HEPES (PEG: Roche Molecular Biochemicals) pre-heated to 37°C was added smoothly and progressively over 1 min with gentle rotation to ensure even mixing. The  
10 cell/PEG mixture was incubated for 1 min at 37°C with gentle agitation. 1 ml of DMEM was added over 1 min at 37°C with gentle agitation. The mixture was incubated for 1 min at 37°C with gentle agitation. A further 1ml of DMEM was added over 1 min at 37°C with gentle agitation and incubated similarly for a further minute. 7mls of HM20 were added over 3 min at 37°C with gentle agitation. The Tube was then spun at 90g for 5 min with  
15 brake. The supernate was aspirated to waste and resuspended in 200ml of HM20/HCF/OPI/AH (HM20/HCF/OPI plus 10% Azaserine Hypoxanthine (Sigma).

The post-fusion mixture was then plated out into 20 96-well sterile plates at 100µl/well and transferred to a 37°C incubator with 5% CO<sub>2</sub>

### Cell Culture

20 On the third day following the fusion cells were transported from the incubator to the work deck and a further 100µl HM20/HCF/OPI/AH was added. The plates were then returned to the incubator.

On day 7 the plates were once again transported from incubator to work deck and 200µl/well was aspirated to waste and replaced with 150µl fresh HM20/HCF.

25 On day 11 the plates were transported to the work deck and 30µl of supernate was collected from each well (Temo head: Tecan Inc.) and transferred to 384-well plates supplied to the workdeck by a carousel plate stacker (Tecan Inc).

### Microarray screening.

Aminosilane coated glass slides were homogenously coated with purified antigen by dropping 40µl of ddH<sub>2</sub>O containing 1-5 µg of antigen and covering with a 22\*60mm coverslip for 60min in a humid chamber at RT.

- 5 Coated slides were rinsed briefly in PBS and blocked for 60' in 5% milk in PBS, 0.1% Tween, then washed for 10' in PBS. The chips were then dried by centrifugation, 10'' at 2000 rpm.

Culture supernatants were consolidated into 384 well plates using a Beckman Biomek FX robot.

- 10 Culture supernatants were printed singularly onto three identical antigen-coated slides at a density of 9600 spots per chip and a spot size of ~120µm using a GeneMachines OmniGrid microarray printer.

The microarray chips were incubated in a humid chamber for 60', at RT and then washed 5 x 5' in PBS-0.1% Tween (PBST)

- 15 40µl of Cy3 conjugated goat anti-mouse IgG-specific and Cy5 conjugated goat anti-mouse IgM-specific antibodies were diluted 1:1000 in PBST, mixed and applied uniformly to the chips and covered with 22x60 mm coverslips and incubated in a humid chamber, for 30' at RT. The chips were then washed 2 x 10' in PBST, 2 x 10' in PBS and 1 x 10' in ddH<sub>2</sub>O. The chips were dried by centrifugation at 2000 rpm for 10''.

### 20 Hit-Picking

Chips were scanned with a GenePix 4000B scanner (Axon Instruments), at a resolution of 10' um.pixel<sup>-1</sup>. PMT voltages were 540V and 610V, for the Cy3 and Cy5 channels respectively. Both lasers were set at 100% intensity. Each scanned chip was assigned a fitted grid, and all spots were analysed by the GenePix Pro 3.0 (Axon Instruments).

- 25 All chips were analysed by the GenePix Pro 3.0 software and we collected, for each chip, the information relative to the corrected intensity ( $I_c$ ) of each spot (Median of intensities – Background), for the Cy3 and Cy5 channels. From this data, we obtained, for each chip, the contribution of each spot to the total Corrected Intensity of each channel

$\left( \frac{I_c}{\sum_1^{9600} I_c} \right) \times 100$ ). The three values of each channel were averaged for each spot, and

this Average Corrected Intensity ( $I_a$ ) was used for the final analysis of the dataset. We considered as “likely to be positive” samples the ones that have a value above 0.5% and as “sure positives”, all the samples showing a value superior to 1.5%.

### Post Screening Processing

- 5 Cells from positive wells were resuspended in the well and 20 $\mu$ l transferred to a 96-deep-well plate previously filled with 1.5mls of HM20/HCF and returned to the incubator for 48hrs at 37°C, 5%CO<sub>2</sub>.

- 1.4ml of culture each supernate was transferred to another deep well plate and the remaining 100 $\mu$ l used to resuspend the cells which were then transferred to a freezing vial  
10 containing 90% Foetal bovine serum/10%DMSO (Sigma) and transferred to -80°C for 2hrs and from there to liquid nitrogen store. Culture supernate was then used for evaluation and further characterization of the generated monoclonal antibody.

### Results:

- The results of microarray screening are shown in Figure 1. This Figure demonstrates that a  
15 number of positive monoclonal antibodies were detected as binding to candidate antigens on the slide. When a comparative experiment was conducted using ELISA in the place of a protein chip, a number of monoclonal antibodies identified as binding to candidate antigens in the microarray screening were not identified as binding to candidate antigens using ELISA, as shown in Figure 2 (see comparison of microarray results with ELISA  
20 results). It is important to note how the supernatants that were negative in the ELISA experiment can be actual positive samples as detected by the more accurate and sensitive microarray approach.

**References**

Kilpatrick *et al* (1997) *Hybridoma* 16: 381-389

Kohler G, Milstein C (1975) *Nature* 7: 256:485-7

Lindley *et al* (2000) *J Immunol Methods* 234: 123-135

5 Ziaudin J, Sabatini D (2001) *Nature* 411: 107-110

Zimmermann U. (1990) *J Immunol Methods* Nov 6;134(1):43-50

## Claims

1. A method for producing a monoclonal antibody, said method comprising the steps of:
  - a) introducing at least one candidate antigen into an animal;
  - 5 b) recovering antibody-producing cells from said animal and rendering these cells into a single cell suspension;
  - c) generating an immortalized cell line from said single cell suspension;
  - d) screening the supernatant of said immortalized cell line against a protein chip on which the candidate antigen is displayed; and
  - 10 e) selecting as said monoclonal antibody, an antibody that binds to said candidate antigen.
2. The method of claim 1 wherein said animal is a mouse, a rat, a guinea pig or a rabbit.
3. The method of claim 1 or claim 2 wherein said candidate antigen is a purified candidate antigen.
- 15 4. The method of claim 3 wherein between one and fifty different purified candidate antigens are introduced into the animal.
5. The method of claim 4 wherein between 0.001 and 1000 micrograms of each antigen is introduced into the animal.
6. The method of any one of claims 1 to 5 comprising the additional step of supplying the
 - 20 animal with a booster dose of some or all of the antigens which were introduced into the animal prior to the removal of antibody-producing cells.
7. The method of any one of claims 1 to 6 wherein the antibody-producing cells are B cells, T cell or stem cells.
8. The method of any one of claims 1 to 7 wherein the antibody-producing cells are
 - 25 recovered by removal of spleen tissue, lymph nodes or bone marrow of the animal.
9. The method of any one of claims 1 to 8 wherein the immortalized cell line is a hybridoma cell line produced by somatic fusion of the cells in the single cell suspension to myeloma cells.
10. The method of any one of claims 1 to 9 wherein said protein chip is a plain-glass slide,
 - 30 a 3D gel pad chip, a microwell chip or a cell chip.



11. The method of any one of claims 1 to 10 wherein the step of detecting the monoclonal antibodies bound to the antigens further comprises isotyping the monoclonal antibodies.
12. The method of claim 11 wherein said step of detecting and isotyping the monoclonal antibodies comprises adding isotype specific anti-immunoglobulin antibodies to said protein chip, wherein each anti-immunoglobulin antibody having a different isotype specificity has a different label, and detecting the presence of said labels.
13. The method of any one of claims 1 to 12 further comprising assessing the specificity with which each isolated monoclonal antibody binds to an antigen using a protein chip comprising said antigen.
14. A method for producing an immortalised cell line that produces a monoclonal antibody of interest, said method comprising the steps of:
  - a) introducing at least one candidate antigen into an animal;
  - b) recovering antibody-producing cells from said animal and rendering these cells into a single cell suspension;
  - c) generating an immortalized cell line from said single cell suspension;
  - d) screening the supernatant of said immortalized cell line against a protein chip on which the candidate antigen is displayed; and
  - e) selecting as said immortalised cell line, that which produces a supernatant containing an antibody that binds to said candidate antigen.
15. An immortalised cell line isolated by the method of claim 14.
16. A method for producing a plurality of monoclonal antibodies, each of which binds to a different purified candidate antigen, comprising introducing a plurality of purified candidate antigens into an animal, each purified candidate antigen being derived from a different source.
17. A method according to claim 16 which further comprises any of the steps recited in any one of claims 1 to 13.
18. A monoclonal antibody isolated by the method of any one of claims 1, 14, 16 or 17.
19. An antibody according to claim 18 which is an anti-idiotypic antibody.

20. An antibody according to claim 19 which is an anti-anti-idiotypic antibody.
21. An immortalized cell line producing a monoclonal antibody of claim 18, claim 19 or claim 20.
22. An immortalized cell according to claim 21 which is a hybridoma cell line.
- 5 23. A bank of antibodies according to claim 18, claim 19 or claim 20.
24. A bank of immortalized cell lines according to claim 15, claim 21 or claim 22.

FIG. 1





FIG. 2



THE PATENT OFFICE

12 MAY 2003

Received in Patents  
International Unit